Ethosuximide granules - Advicenne Pharma

Drug Profile

Ethosuximide granules - Advicenne Pharma

Alternative Names: ADV-6770

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advicenne
  • Class Antiepileptic drugs; Small molecules; Succinimides
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Absence epilepsy

Most Recent Events

  • 05 Oct 2017 Advicenne Pharma plans the KIEKIDS A11CS phase II trial for Absence epilepsy in France (EudraCT2016-002313-22)
  • 01 Oct 2015 Phase-I clinical trials in Absence epilepsy (In infants, In children, In adolescents) in France (unspecified route) (before October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top